Google will no longer sell Glass Enterprise smart glass, according to the company website. The decision marks the end of the most recognizable line of smart glasses, which first launched in 2013 for a whopping $1,500.
"Thank you for over a decade of innovation and partnership," read a message from Google. "As of March 15, 2023, we will no longer sell Glass Enterprise Edition. We will continue supporting Glass Enterprise Edition until September 15, 2023."
While Google pitched augmented reality (AR) glasses as a major innovation in consumer technology, it never gained mainstream popularity. The tech giant was more successful selling it to companies looking to use it for more specialized work purposes.
That pivot came in 2017, and an updated version of Glass Enterprise was released in 2019.
Existing units will continue working through September 15th. Then Google will no longer provide software updates.
What this means for the future of AR is unclear. No specific plans have been announced, but Google said it remains interested in the concept.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
